Evolus’ (EOLS) Buy Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Evolus (NASDAQ:EOLS) in a research note published on Friday, Benzinga reports. They currently have a $22.00 price target on the stock.

EOLS has been the subject of a number of other research reports. HC Wainwright reaffirmed a buy rating and issued a $27.00 price objective on shares of Evolus in a report on Thursday, August 1st. Cantor Fitzgerald reaffirmed an overweight rating on shares of Evolus in a report on Monday, September 9th.

Evolus Stock Up 6.3 %

Shares of NASDAQ:EOLS opened at $17.49 on Friday. Evolus has a 12-month low of $7.44 and a 12-month high of $17.59. The company has a current ratio of 2.92, a quick ratio of 2.67 and a debt-to-equity ratio of 6.26. The firm has a market cap of $1.10 billion, a PE ratio of -16.66 and a beta of 1.31. The company has a fifty day simple moving average of $13.63 and a 200 day simple moving average of $13.04.

Evolus (NASDAQ:EOLS) last issued its earnings results on Wednesday, July 31st. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). The firm had revenue of $66.91 million for the quarter, compared to analyst estimates of $65.06 million. On average, equities research analysts anticipate that Evolus will post -0.64 EPS for the current fiscal year.

Insider Activity

In related news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $15.85, for a total value of $89,251.35. Following the sale, the chief marketing officer now owns 82,375 shares of the company’s stock, valued at approximately $1,305,643.75. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Evolus news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the business’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $15.85, for a total transaction of $89,251.35. Following the completion of the transaction, the chief marketing officer now owns 82,375 shares in the company, valued at approximately $1,305,643.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Sandra Beaver sold 3,276 shares of the firm’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $14.98, for a total value of $49,074.48. Following the transaction, the chief financial officer now directly owns 148,502 shares in the company, valued at $2,224,559.96. The disclosure for this sale can be found here. Corporate insiders own 6.10% of the company’s stock.

Institutional Trading of Evolus

Institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets raised its holdings in Evolus by 84.2% during the first quarter. BNP Paribas Financial Markets now owns 405,931 shares of the company’s stock worth $5,683,000 after purchasing an additional 185,532 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in Evolus during the first quarter valued at about $1,907,000. Trexquant Investment LP grew its holdings in Evolus by 74.9% during the fourth quarter. Trexquant Investment LP now owns 158,075 shares of the company’s stock worth $1,665,000 after acquiring an additional 67,678 shares during the period. Perceptive Advisors LLC raised its position in Evolus by 166.8% in the fourth quarter. Perceptive Advisors LLC now owns 3,963,424 shares of the company’s stock worth $41,735,000 after acquiring an additional 2,477,623 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its holdings in Evolus by 5,627.2% in the 2nd quarter. Assenagon Asset Management S.A. now owns 947,103 shares of the company’s stock valued at $10,276,000 after acquiring an additional 930,566 shares during the last quarter. 90.69% of the stock is owned by institutional investors and hedge funds.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.